Leibovitz E, Janco J, Piglansky L, Press J, Yagupsky P, Reinhart H, Yaniv I, Dagan R
Pediatric Infectious Disease Unit, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Pediatr Infect Dis J. 2000 Nov;19(11):1060-7. doi: 10.1097/00006454-200011000-00006.
Acute invasive diarrhea is a potentially serious condition in children. Because of the increasing resistance of enteric pathogens to commonly used oral antibiotics, intramuscular ceftriaxone has become the routine drug in the treatment of acute invasive diarrhea requiring an emergency visit in southern Israel. The inconvenience of this parenteral regimen created an increased need for oral pediatric formulations for the treatment of invasive diarrhea.
To evaluate the efficacy and safety of a suspension formulation of ciprofloxacin in the treatment of acute invasive diarrhea in infants and children.
From July 1996 through December 1997, 201 evaluable children ages 6 months to 10 years (35% <1 year; 70% <3 years) presenting with acute invasive diarrhea at the Pediatric Emergency Room were randomized to receive either ciprofloxacin suspension (10 mg/kg twice a day + im placebo; n = 95) or im ceftriaxone (50 mg/kg/day + placebo suspension; n = 106) for 3 days in a double blind manner. Stool cultures for Shigella, Salmonella, Campylobacter spp. and diarrheagenic Escherichia coli were obtained on Days 1, 3, 4 to 5 and 21 +/- 5. Clinical response and safety were assessed on Days 1, 2, 3, 4 to 5 and 21 +/- 5.
We isolated 127 pathogens from 121 (60%) patients: 73 (57%) Shigella; 23 (18%) Salmonella; 18 (14%) E. coli; and 13 (10%) Campylobacter. Overall bacteriologic eradication on Day 4 to 5 was 99% for Shigella, 77% for Salmonella and 77% for Campylobacter, with no difference between the 2 groups. Clinical cure or improvement was observed in 100 and 99% of the ciprofloxacin and ceftriaxone groups, respectively. Serum ciprofloxacin values determined on Day 3 of the treatment were higher in the majority of patients than were the MIC50 and MIC90 values for the Shigella and Salmonella spp. isolated. Possible drug-related adverse events occurred in 13 patients [ciprofloxacin, 8 (8%); ceftriaxone, 5 (4.7%)] and were mild and transient. Joint examination was normal during and after completion of therapy in all patients.
Oral ciprofloxacin was as safe and effective as intramuscular ceftriaxone for the empiric treatment of acute invasive diarrhea in ambulatory pediatric patients requiring an emergency room visit.
急性侵袭性腹泻在儿童中是一种潜在的严重病症。由于肠道病原体对常用口服抗生素的耐药性不断增加,在以色列南部,肌肉注射头孢曲松已成为治疗需要急诊的急性侵袭性腹泻的常规药物。这种肠胃外给药方案带来的不便使得对治疗侵袭性腹泻的口服儿科制剂的需求增加。
评估环丙沙星混悬液治疗婴幼儿和儿童急性侵袭性腹泻的疗效和安全性。
1996年7月至1997年12月,201名年龄在6个月至10岁(35%小于1岁;70%小于3岁)、在儿科急诊室出现急性侵袭性腹泻的可评估儿童被随机分为两组,以双盲方式接受环丙沙星混悬液(10mg/kg,每日两次+肌肉注射安慰剂;n=95)或肌肉注射头孢曲松(50mg/kg/天+安慰剂混悬液;n=106)治疗3天。在第1、3、4至5天以及21±5天采集粪便样本进行志贺菌、沙门菌、弯曲菌属和致泻性大肠杆菌的培养。在第1、2、3、4至5天以及21±5天评估临床反应和安全性。
我们从121名(60%)患者中分离出127种病原体:73种(57%)志贺菌;23种(18%)沙门菌;18种(14%)大肠杆菌;13种(10%)弯曲菌。在第4至5天,志贺菌的总体细菌清除率为99%,沙门菌为77%,弯曲菌为77%,两组之间无差异。环丙沙星组和头孢曲松组分别有100%和99%的患者实现临床治愈或病情改善。在治疗第3天测定的多数患者血清环丙沙星值高于分离出的志贺菌和沙门菌属的MIC50和MIC90值。13名患者出现可能与药物相关的不良事件[环丙沙星组8例(8%);头孢曲松组5例(4.7%)],且症状轻微且短暂。所有患者在治疗期间及治疗结束后关节检查均正常。
对于需要急诊室就诊的门诊儿科患者,口服环丙沙星在经验性治疗急性侵袭性腹泻方面与肌肉注射头孢曲松同样安全有效。